The market for synthetic drugs—amphetamines, methamphetamine and ecstasy (MDMA), as well as synthetic versions of cannabis and of opioids such as heroin—runs into the billions of euros each year, and the sophistication of producers and traffickers continues to rise.
Drug trafficking is one of the EMPACT priorities, Europol’s priority crime areas, under the 2018–2021 EU Policy Cycle.
The production of synthetic drugs is getting more sophisticated; distribution networks, nimbler and smarter; and the drugs themselves, more harmful. Markets are continually diversifying, with prescription medicines and new synthetic opioids increasingly being misused.
A large number of new psychoactive substances (NPSs) are being sold openly as “legal” replacements for illicit drugs: hundreds of new substances have been reported in the last few years alone, and the EU Early Warning System now has over 500 on its radar.
Production, marketing and distribution
The production of synthetic drugs is becoming more sophisticated and diverse—and there are greater opportunities for drugs to be produced nearer to consumer markets in the EU. Aggressive marketing is becoming more apparent in the ecstasy market, as competition among suppliers heats up.
The market for opioid drugs is becoming more dynamic and more complex. Consumption patterns are influenced by availability. Although heroin still predominates, the market is also shifting to other opioids or stimulants, including NPSs. Sometimes new substances are used as temporary replacements for illicit drugs—and they can even displace them altogether, either for some time or permanently.
Innovation and destruction
As a general matter, suppliers of synthetic drugs care less about a specific substance and more about mimicking the pharmacological effects of the original: for instance, each synthetic cannabinoid that is produced is disposable: once it has been banned—or is about to be—a “legal” replacement appears.
The damage done
The products of all this creativity cause a wide range of harmful outcomes, such as serious, sometimes fatal, poisonings. And changes in how users inject themselves as they switch to new substances have also caused mass poisonings and outbreaks of infections such as HIV, hepatitis C and bacterial illnesses: in the past few years the EMCDDA has put out tens of alerts on outbreaks of this kind.
The use of stimulants leads not only to problems related to fatigue, but to short-term psychotic episodes. In general, it is associated with high rates of psychiatric problems.
The availability of high-dose MDMA (“ecstasy”) products also constitutes an emerging threat. Following recent shortages, the drug is once more widely available. And consumer interest in this drug is once again on the rise.
The dumping of toxic waste from the production of stimulants also poses health risks and causes environmental damage.
The EU Drugs Strategy (2013–20) and its associated action plans provide a framework for addressing illicit drugs in the EU, thus complementing Member States’ national strategies and supporting joint actions. The overarching objective of the Strategy is to cut the availability of illicit drugs by:
- disruption trafficking
- dismantling organised crime groups (OCGs) involved in production and trafficking
- using the criminal justice system
- deploying intelligence-led law enforcement effectively
- increasing the sharing of intelligence sharing
- specifically targeting large-scale, cross-border and organised drug-related crime
The Strategy and its action plans are producing results: every year there are tens of thousands seizures of new substances such as synthetic cannabinoids and cathinones, tranquilisers and fentanyls (which may be sold as heroin)—many vastly more potent than their controlled counterparts.